Exclusive Callan Study Examines Fees for Real Assets Funds
"What stands out in the study is how many institutional open-end options exist today and how seemingly minor differences in fees and terms can impact investors," said author
The study is intended to help institutional investors better evaluate open-end real assets funds, serving as an industry benchmark when comparing a partnership's terms to its peers. The study can also be useful for real assets investment managers to determine how their fees and terms compare to other managers.
Key Findings
- The median management fee for core real estate equity funds is 96 basis points (based on
$25 million net asset value). - 55 of 144 open-end real assets funds charge performance fee, the vast majority being European waterfalls.
- 63% of open-end real assets fund have a redemption queue that is pro rata based on NAV, and 53% have redemption notice periods of 90 days.
Conclusions
Investors have no shortage of options: There continues to be strong demand among investors for open-end real assets funds, with managers launching new open-end funds and competition increasing in most strategy types analyzed in the study.
Fees and terms can be a differentiator: As fees and terms may vary widely depending on the strategy, funds offering more investor-friendly fees and terms can be more competitive in searches.
The devil is in the details: While some open-end fund terms are relatively standardized across the universe, certain nuances such as redemption notice periods and queue methodology can have meaningful implications for investors when they need liquidity.
The study features data from the proprietary survey Callan conducted, data provided by investment managers in the firm's database CallanDNA, as well as data from fund documents reviewed as part of Callan's due diligence process.
Find the summary blog post and study here.
About Callan
Callan was founded as an employee-owned investment consulting firm in 1973. Ever since, we have empowered institutional clients with creative, customized investment solutions backed by proprietary research, exclusive data, and ongoing education. Today, Callan advises clients with more than
Media Contact:
[email protected]
415-274-3020
View original content to download multimedia:https://www.prnewswire.com/news-releases/exclusive-callan-study-examines-fees-for-real-assets-funds-302325190.html
SOURCE Callan LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ekinops Announces Framework Agreement with Proximus to deploy a nationwide high-speed optical network across Belgium
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
- Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share